Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at approximately $1.1 billion.   Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash.  ...